Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis

Rheumatology and Therapy, 2016 07: 1-14

Biologic therapies have improved the clinical management of ankylosing spondylitis (AS). Few head-to-head studies have directly compared the efficacy of these agents. This study was conducted to indirectly compare the efficacy of biologic agents for treatment of active AS.

View abstract

Authors

Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A.